Therapeutic adherence: A prospective drug utilization study of oral hypoglycemic in patients with type 2 diabetes mellitus

Asian Pacific Journal of Tropical Disease

Volumn 4, Issue S1, 2014, Pages

  Khan, Gulam Haidar ^a   Aqil, Mohd ^b   Pillai, Krishna Kolappa ^b   Ahmad, Md Afroz ^b   Kapur, Prem ^c   Ain, Md Ruhal ^d   Al Ghamdi, Saeed Saeed ^e   Shahzad, Naiyer ^e  

^a NOVARTIS HEALTHCARE PVT LTD   (India)

^b HAMDARD UNIVERSITY   (India)

^c HAMDARD UNIVERSITY   (India)

^d NIMS UNIVERSITY   (India)

^e UMM AL QURA UNIVERSITY   (Saudi Arabia)

Author keywords

Adherence; Diabetes mellitus; Drug utilization; Oral hypoglycemic agents

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; VOGLIBOSE;

ADULT; AGED; ARTICLE; DIABETIC DIET; DIABETIC PATIENT; DRUG CHOICE; DRUG UTILIZATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; STRUCTURED QUESTIONNAIRE; TEACHING HOSPITAL; TREATMENT DURATION;

EID: 84893460086     PISSN: 22221808     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2222-1808(14)60469-2     Document Type: Article

References (37)

1. American Diabetes Association Standards of medical care in diabetes-2009. Diabetes Care 2009, 32:S13-S61.
2. Wild S, Roglic G, Green A, Sicree R, King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. Shankar UV, Kasia L, Mini GK, Sarma PS, Thankappan KR The adherence to medications in diabetic patients in rural Kerala, India. Asia Pac J Public Health 2013 Feb 14, [Epub ahead of print].
4. Pradeepa R, Mohan V The changing scenario of the diabetes epidemic: implications for India. Indian J Med Res 2002, 116:121-132.
5. Pradeepa R, Deepa R, Mohan V Epidemiology of diabetes in India-current perspectives and future projections. J Indian Med Assoc 2002, 100:144-148.
6. Ramachandran A, Snehalatha C, Vijay V Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract 2004, 65:189-195.
7. Sultana G, Kapur P, Aqil M, Alam MS, Pillai KK Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J Clin Pharm Ther 2010, 35:267-277.
8. Holmann RR, Cull CA, Turner RC A randomized double-blind trial of acarbose in type2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care 1999, 22:960-964.
9. Parthasarthi G, Hansen KN, Nahata MC A textbook of clinical pharmacy practice: essential concepts and skills 2004, 496. Orient Blackswan, India.
10. Morisky DE, Ang A, Krousel-Wood M, Ward HJ Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008, 10(5):348-354.
11. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, et al. Medication adherence and associated hemoglobin HbA1c in type 2 diabetes. Ann Pharmacother 2004, 38:1357-1362.
12. Morisky DE, Green LW, Levine DM Concurrent and predictive validity of a self reported measure of medication adherence. Med Care 1986, 24:67-74.
13. Mino-León D, Figueras A, Amato D, Laporte JR Treatment of type 2 diabetes in primary health care: a drug utilization study. Ann Pharmacother 2005, 39:441-445.
14. Mukhyaprana MP, Vidyasagar S, Shashikiran U Clinical profile of type 2 diabetes mellitus and body mass index-Is there any correlation. Calicut Med J 2004, 2:e3.
15. Sutharson L, Hariharan RS, Vamsadhra C Drug utilization study in diabetology out patient settings of a tertiary hospital. Indian J Pharmacol 2003, 35:237-240.
16. Bocuzzi JS, Wogen J, Fox J, Sung JC, Shah AB, Kim J Utilization of oral hypoglycemic agents in drug-insured US population. Diabetes Care 2001, 24:1411-1415.
17. Vikram NK, Misra A, Pandey M, Dudeja V, Sinha S, Ramadevi J, et al. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. Diabetes Nut Metab 2003, 16:32-40.
18. Ramachandran A, Snehalatha C, Vishwanathan V Burden of type 2 diabetes and its complications - the Indian scenario. Curr Sci 2002, 83:1471-1476.
19. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001, 44:1094-1101.
20. Prasanna KK, Ravi TM Effect of moringa oleifera on blood glucose, ldl levels in types 2 Diabetic obese people. Innovative J Med Health Sci 2013, 3(1):23-25.
21. Ramachandran A, Snehalatha C, Vishwanathan V, Viswanathan M, Haffner SM Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract 1997, 36:121-125.
22. Ramachandran A, Snehalatha C, Vijay V Temporal changes in prevalence of type 2 diabetes and impaired glucose tolerance in urban southern India. Diabetes Res Clin Pract 2002, 58:55-60.
23. Lau GS, Chan JC, Chu PL, Tse DC, Critchely JA Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hongkong. Ann Pharmacother 1996, 30:232-237.
24. Doró P, Benko R, Kosik E, Matuz M, Tóth K, Soós G Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol 2005, 61:893-897.
25. Al Khaja KA, Sequeira RP, Mathur VS Prescribing patterns and therapeutic implications for diabetic hypertension in Bahrain. Ann Pharmacother 2001, 35:1350-1359.
26. UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
27. Wadher KJ, Kalsait RP, Kakde RB, Umekar MJ Metformin: a review on therapeutic role in diabetes mellitus and cardiovascular disorder. Int J Pharm Sci Rev Res 2011, 10(1):147-151.
28. Bailey CJ, Turner RC Metformin. N Engl J Med 1996, 334:574-579.
29. Clark HE, Mathews DR The effect of glimepiride on pancreatic beta-cell function under hyperglycemic clamp and hyperinsulinaemic, eulglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996, 28:445-450.
30. Holstein A, Plaschke A, Egberts EH Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17(6):467-473.
31. Defronzo RA Pharmacological therapy for type2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
32. Gerich JE Oral hypoglycemic agents. N Engl J Med 1989, 321:1231-1245.
33. Cohen FJ, Neslusan CA, Conklin JE, Song X Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 2003, 26:1847-1851.
34. Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004, 38:1357-1362.
35. Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HG, et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?. Pharmacoepidemiol Drug Saf 2003, 12:121-127.
36. Paes AH, Bakker A, Soe-Agnie CJ Impact of dosing frequency on patient compliance. Diabetes Care 1997, 20:1512-1517.
37. Guillausseau PJ Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003, 29:79-81.